Patent Application Titled "Pharmaceutical Composition Comprising Anti-Connective Tissue Growth Factor Antibody" Published Online (USPTO 20230416352).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      The US Patent and Trademark Office has published a patent application for a pharmaceutical composition that includes an anti-Connective Tissue Growth Factor (CTGF) antibody. The composition, developed by inventors from Shanghai, China and assigned to Jiangsu Hengrui Pharmaceuticals Co. Ltd., is stable and suitable for lyophilization. The patent application provides specific sequences for the antibody's heavy chain and light chain variable regions, as well as their identities to known sequences. The anti-CTGF antibody has potential therapeutic applications in various diseases, including renal diseases, liver fibrosis, myocardial infarction, and pulmonary fibrosis. [Extracted from the article]
    • Abstract:
      Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)